Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 570-573, 2002;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bateman, R. M.
Right arrow Articles by Freeman, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bateman, R. M.
Right arrow Articles by Freeman, D. J.
Related Collections
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:570-573.)
© 2002 American Association for Clinical Chemistry, Inc.


Technical Briefs

Optimization of Nitric Oxide Chemiluminescence Operating Conditions for Measurement of Plasma Nitrite and Nitrate

Ryon M. Bateman1,2, Christopher G. Ellis1,2 and David J. Freeman1a

1 Vascular Biology Program, Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, N6B 1B8 Canada
Departments of
2 Medical Biophysics and
3 Medicine, University of Western Ontario, London, Ontario, N6A 5C1 Canada

aaddress correspondence to this author at: Department of Medicine, University of Western Ontario, University Hospital 339 Windermere Rd., London, Ontario, N6A 5A5 Canada; fax 519-663-3789, e-mail dfreeman{at}uwo.ca

The oxidized nitric oxide (NO) metabolites nitrite (NO2-) and nitrate (NO3-) have been used as markers of NO synthase activity in several clinical and experimental studies including those investigating sepsis (1)(2)(3)(4), septic shock (5), endotoxemia (6)(7), cardiac transplant (8), hypertension (9), and cancer (10). Although the NO chemiluminescence methodology has been used to measure NO2- and NO3- (11)(12)(13), there are few reports evaluating the operating conditions of the assay.

The operating efficiency of the NO chemiluminescent system is governed by several variables: driving pressure and flow rate of the carrier gas (14)(15), which determine the degree of mixing in reducing solution and dispersion of NO in the carrier gas stream; chemiluminescent reaction chamber pressure (PRC); and the selectivity (16), pH (11), temperature (13), and concentration of the reducing agents used to convert NO2- and NO3- to NO. Yang et al. (13) studied the efficiency of conversion of both NO2- and NO3- to NO using various reducing agents over a range of operating temperatures; however, no studies on the relationship between carrier gas flow rate and PRC have been reported.

The present study had three primary objectives: (a) to determine the optimal operating conditions for carrier gas flow rate and PRC to achieve maximum efficiency of the chemiluminescent response for both NO2- and NO3- determinations; (b) to determine the detection limit and linearity of NO2- and NO3- responses on the basis of these optimal operating conditions; and (c) to evaluate the recovery of NO2- and NO3-from plasma and deproteinized plasma under optimized operating conditions.

We purchased potassium iodide, sodium nitrite, sodium nitrate, and glacial acetic acid from Sigma, vanadium (III) trichloride, and hydrochloric acid from Aldrich Chemical Co., and helium and oxygen from Praxair.

The NO chemiluminescence system used in these experiments consisted of four main components: helium carrier gas (set at 35 psi), two in-parallel purge vessels with condensers connected by T-valves, a nitric oxide analyzer (NOA) with inlet valve and chemiluminescence reaction chamber (Sievers 270B, NO Chemiluminescence Analyzer, Sievers Instruments), and a vacuum pump (Edwards Pump) to draw the carrier gas into the reaction chamber. Helium carrier gas passed through a chemical trap (2 mol/L NaOH) before entry into the NOA to remove volatile acids. Connecting tubing was 3.2 mm i.d. (890 FEP; Nalge Nunc International). One purge vessel (10-mL capacity) was dedicated to KI reduction at room temperature, whereas the other (12 mL-capacity and fitted with a cold-water condenser) was dedicated to V(III) reduction at 90 °C. The helium flow rate into either purge vessel was controlled by a flow meter (Matheson Gas Products) placed upstream of the purge vessels. Operating pressure of the NO chemiluminescence reaction chamber was controlled by a needle valve at the entrance to the NOA. Inlet oxygen pressure, used to generate ozone, was 6 psi. In brief, NO2- or NO3- calibrators were injected (10 µL) into a purge vessel containing either KI or V(III) and converted to NO. NO was then stripped from the reducing medium by a helium carrier gas and transported, via the chemical trap, to the chemiluminescence reaction chamber where it reacted with ozone to generate the chemiluminescent signal as described previously (17).

Operating conditions were adjusted to evaluate efficiency of the NO chemiluminescent response at different gas flow rate and PRC combinations. Plots of NO chemiluminescence responses for various flow rates against PRC are called isoflow curves. The strength, concentration, and temperature of reducing agents used were established according to recommendations from the NOA manufacturer (18) and by Yang et al. (13). NO2- was reduced to NO in KI solution (50 mg · 1 mL-1 of water · 4 mL-1 of glacial acetic acid) at room temperature (22 °C) to minimize foaming of the reducing solution. NO3- was reduced to NO in V(III) (3.5 mL; 0.05 mol/L in 0.8 mol/L HCl) at 90 °C.

Aqueous 30 µmol/L calibrator samples of NO2- and NO3- were prepared by diluting NO2- and NO3- into deionized water or fresh plasma obtained from heparinized rat whole blood. Plasma samples were also deproteinized by acetonitrile (1:1 by volume) to limit potential interference from hemoglobin (17). Supernatants were collected by centrifugation (3000g for 3 min at 4 °C).

Kruskal–Wallis one-way ANOVA on ranks was used to assess differences in the time of NO chemiluminescence signal onset over various operating conditions (SigmaStat 2.0; SPSS Inc.). Dunnett’s method was used for pairwise multiple comparison with the highest flow group (flow rate, 126 mL/min) acting as the control group. Regression analysis was performed with SigmaPlot 5.00 (SPSS Inc. Chicago, IL). P <0.05 was considered statistically significant.

Isoflow curves of NO chemiluminescence responses from 300 pmol of NO2- and NO3- in both aqueous solution and plasma are depicted in Fig. 1 . In all cases, for a given flow rate, the maximum NO signal was dependent on PRC. As helium carrier gas flow rates increased, from 42 to 126 mL/min, maximum NO signal response was obtained at increasingly higher PRC. These responses demonstrated that the maximum NO signal was dependent on both flow rate and PRC.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 1. Isoflow profiles for aqueous and plasma NO2- and NO3- conversion to NO under various flow rate and PRC combinations.

Isoflow profiles for conversion of 300 pmol of NO2- to NO in aqueous solution and plasma by KI in glacial acetic acid at 22 °C (A and B) and 300 pmol of NO3- to NO in aqueous and plasma solution by V(III) at 90 °C (C and D). Endogenous plasma background NO2- and NO3- responses were not subtracted from the sample NO chemiluminescent signal.

The detection limit and linearity of the NO chemiluminescent response for aqueous NO2- and NO3- conversion to NO at optimal low (flow rate, 42 ml/min; PRC, 1133 Pa), medium (flow rate, 69 ml/min; PRC, 1100 Pa), and high (flow rate, 126 ml/min; PRC, 1100 Pa) flow rate states are shown in Table 1 . Both the detection limit and linear range were dependent on operating conditions with the lowest detection limit and greatest linear range being achieved at a high flow rate. Although greater NO signals were obtained at a low flow rate, detection limit was improved at a high flow rate because the signal-to-noise ratio was increased. Additionally, the onset of NO signal at the high flow rate (12.8 ± 0.2 s) decreased (P < 0.05) compared to low flow rate (29.4 ± 0.2 s). Under high flow rate conditions, recovery of nitrite (10–100 000 pmol) in plasma and deproteinized plasma ranged from 92.2% ± 6.8% to 100.2% ± 2.5% and 87.3% ± 5.5% to 111.7% ± 8.9%, respectively. Nitrate recovery (10–100 000 pmol) was similar (i.e., in plasma, 101% ± 2.3% to 96.1% ± 1.2%; in deproteinized plasma, 89% ± 1.6% to 101.7% ± 2.2%, respectively). Recovery at 1 pmol, although detectable, was not readily quantifiable electronically because of increased background signal. The decrease in sensitivity in plasma, relative to aqueous samples, was attributable to increased background signal in both plasma and deproteinized plasma.


View this table:
[in this window]
[in a new window]
 
Table 1. Effect of operating conditions on NO chemiluminescence signal detection limit and linearity.

Isoflow curves show that NO chemiluminescent signal is dependent on both flow velocity of helium carrier gas and PRC. This is consistent with earlier reports that chemiluminescent signal is related to the rate of carrier gas flow (14)(15). Increasing the rate of the carrier gas into the purge vessel should increase the rate of mass transfer of NO from the liquid phase into the gas phase, thereby increasing the efficiency of the separation process and also decreasing the axial dispersion of the NO in the helium flow stream. However, the probability of a successful collision between NO and ozone within the reaction chamber may decrease because of decreased NO residence time, thereby reducing signal intensity; although, this is offset somewhat by higher PRC, despite the likelihood of enhanced nonradiative collisional quenching of the excited state of NO2 (NO2*) (18).

We determined the maximum NO chemiluminescent signal for all flow rates tested and observed that as flow rates increased, the maximum signal not only decreased, but occurred at higher PRC (Fig. 1Up ). This indicated a complex relationship among flow, PRC, and NO signal. Interestingly, this complex relationship is similar in some respects to the efficiency profile of gas and liquid chromatographic separations, where the maximum efficiency is related to the carrier gas velocity at which the theoretical plate height is minimized (19). At high flow rates, the detection limit was enhanced (Table 1Up ) because of increased peak stability at low concentrations (i.e., electronic area integration was improved.)

In conclusion, a range of carrier gas flow rates have been reported (100 mL/min of N2 to 200 mL/min of helium) for chemiluminescence-based analysis of NO2- and NO3- (11)(12)(13). On the basis of our results, we recommend the use of a high carrier gas/mobile phase flow rate at optimized PRC. Despite a reduction in NO chemiluminescent signal response, this increases sensitivity and linear response of the assay and has the additional benefit of decreasing analysis time.


Acknowledgments

This research was supported by Medical Research Council Grant MA-13941 (to C.G.E.). R.M.B. was supported by the Spoerel Research Fellowship, Department of Anesthesia, University of Western Ontario.


References

  1. Ergenekon E, Gucuyener K, Erbas D, Koc E, Ozturk G, Atalay Y. Urinary nitric oxide in newborns with infections. Biol Neonate 2000;78:92-97.[ISI][Medline] [Order article via Infotrieve]
  2. Satoi S, Kamiyama Y, Kitade H, Kwon AH, Takahashi K, et al. Nitric oxide production hepatic dysfunction in patients with postoperative sepsis. Clin Exp Pharmacol Physiol 2000;27:197-201.[ISI][Medline] [Order article via Infotrieve]
  3. Wong HR, Carcillo JA, Burckart G, Shah N, Janosky JE. Increased serum nitrite and nitrate concentrations in children with the sepsis syndrome. Crit Care Med 1995;23:835-842.[ISI][Medline] [Order article via Infotrieve]
  4. Bateman RM, Jagger JE, Sharpe MD, Ellsworth ML, Mehta S, Ellis CG. Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. Am J Physiol Heart Circ Physiol 2001;280:H2848-H2856.[Abstract/Free Full Text]
  5. Strand OA, Leone A, Giercksky KE, Kirkeboen KA. Nitric oxide indices in human septic shock. Crit Care Med 2000;28:2779-2785.[ISI][Medline] [Order article via Infotrieve]
  6. Brovkovych V, Dobrucki LW, Brovkovych S, Dobrucki I, Kalinowski L, et al. Nitric oxide measurements during endotoxemia. Clin Chem 2001;47:1068-1074.[Abstract/Free Full Text]
  7. Deshmukh DR, Ghole VS, Marescau B, De Deyn PP. Effect of endotoxemia on plasma and tissue levels of nitric oxide metabolites and guanidino compounds. Arch Physiol Biochem 1997;105:32-37.[ISI][Medline] [Order article via Infotrieve]
  8. Benvenuti C, Bories PN, Loisance D. Increased serum nitrate concentration in cardiac transplant patients. A marker for acute allograft cellular rejection. Transplantation 1996;61:745-749.[Medline] [Order article via Infotrieve]
  9. Wu CC, Yen MH. Higher level of plasma nitric oxide in spontaneously hypertensive rats. Am J Hypertens 1999;12:476-482.[ISI][Medline] [Order article via Infotrieve]
  10. Szaleczky E, Pronai L, Nakazawa H, Tulassay Z. Evidence of in vivo peroxynitrite formation in patients with colorectal carcinoma, higher plasma nitrate/nitrite levels, and lower protection against oxygen free radicals. J Clin Gastroenterol 2000;30:47-51.[ISI][Medline] [Order article via Infotrieve]
  11. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989;61:2715-2718.[Medline] [Order article via Infotrieve]
  12. Cox RD, Frank CW. Determination of nitrate and nitrite in blood and urine by chemiluminescence. J Anal Toxicol 1982;6:148-152.[ISI][Medline] [Order article via Infotrieve]
  13. Yang F, Troncy E, Francoeur M, Vinet B, Vinay P, et al. Effects of reducing reagents and temperature on conversion of nitrite and nitrate to nitric oxide and detection of NO by chemiluminescence. Clin Chem 1997;43:657-662.[Abstract/Free Full Text]
  14. Aoki T. Continuous flow determination of nitrite with membrane separation/chemiluminescence detection. Biomed Chromatogr 1990;4:128-130.[Medline] [Order article via Infotrieve]
  15. Pai TG, Payne WJ, LeGall J. Use of a chemiluminescence detector for quantitation of nitric oxide produced in assays of denitrifying enzymes. Anal Biochem 1987;166:150-157.[Medline] [Order article via Infotrieve]
  16. Greenberg SS, Xie J, Spitzer JJ, Wang JF, Lancaster J, et al. Nitro containing L-arginine analogs interfere with assays for nitrate and nitrite. Life Sci 1995;57:1949-1961.[ISI][Medline] [Order article via Infotrieve]
  17. Bateman RM, Ellis CG, Sharpe MD, Mehta S, Freeman DJ. Effect of hemolyzed plasma on the batch measurement of nitrate by nitric oxide chemiluminescence. Clin Chem 2001;47:1847-1851.[Free Full Text]
  18. Operation and Service Manual. Boulder, CO: Sievers Instruments, 1992..
  19. Berezkin VG, Malyukova IV, Avoce DS. Use of equations for the description of experimental dependence of the height equivalent to a theoretical plate on carrier gas. J Chromatogr A 2000;872:111-118.[Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
J AndrolHome page
L. De Young, D. Yu, R. M. Bateman, and G. B. Brock
Oxidative Stress and Antioxidant Therapy: Their Impact in Diabetes-Associated Erectile Dysfunction
J Androl, September 1, 2004; 25(5): 830 - 836.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B. Tribl, R. M. Bateman, S. Milkovich, W. J. Sibbald, and C. G. Ellis
Effect of nitric oxide on capillary hemodynamics and cell injury in the pancreas during Pseudomonas pneumonia-induced sepsis
Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H340 - H345.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bateman, R. M.
Right arrow Articles by Freeman, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bateman, R. M.
Right arrow Articles by Freeman, D. J.
Related Collections
Right arrow Automation and Analytical Techniques


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS